Page last updated: 2024-10-30

leflunomide and Cancer of Head

leflunomide has been researched along with Cancer of Head in 2 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Research Excerpts

ExcerptRelevanceReference
" Currently, SU101 in combination with cytotoxic agents is in late-stage clinical development for the treatment of cancers."1.31Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. ( Cherrington, JM; Kabbinavar, F; Mann, E; Schwartz, DP; Shawver, LK; Slamon, DJ; Strawn, LM, 2000)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stegeman, H1
Kaanders, JH1
Verheijen, MM1
Peeters, WJ1
Wheeler, DL1
Iida, M1
Grénman, R1
van der Kogel, AJ1
Span, PN1
Bussink, J1
Strawn, LM1
Kabbinavar, F1
Schwartz, DP1
Mann, E1
Shawver, LK1
Slamon, DJ1
Cherrington, JM1

Other Studies

2 other studies available for leflunomide and Cancer of Head

ArticleYear
Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.
    Molecular cancer, 2013, Nov-05, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Butadienes; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chemor

2013
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Div

2000